JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Toll, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toll, L.

Comparison of mu opioid receptor binding on intact neuroblastoma cells with guinea pig brain and neuroblastoma cell membranes

L Toll

Department of Neuroscience, SRI International, Menlo Park, California.

To better understand opioid binding parameters found in situ, binding studies were conducted to mu-opioid receptors on intact SH-SY5Y neuroblastoma cells and compared with binding to SH-SY5Y membrane and guinea pig brain membrane preparations. The mu-selective peptide antagonist [3H]D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) was used for the binding studies. The fact that CTOP is an antagonist and hydrophilic is important for binding to be achieved using intact cells. In intact cells, using a physiological buffer, there appears to be only a low affinity "agonist" conformation of the receptor. This is in contrast to binding in either brain or SH-SY5Y membranes in Tris buffer, in which high-affinity agonist binding was prevalent. As expected from the binding profiles, pertussis toxin treatment of cells has no effect on binding to intact cells, but significantly decreases affinity of agonists to cell membranes. In intact cells, binding appears to be to a single site and a single state of the mu receptor. Although in membrane preparations inhibition curves are shallow, with slope factors less than 1.0 for many agonists, on intact cells agonist inhibition curves are very steep, with slope factors slightly greater than 1.0.

Volume 260, Issue 1, pp. 9-15, 01/01/1992
Copyright © 1992 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
Z.-B. You, M. Herrera-Marschitz, and L. Terenius
Modulation of Neurotransmitter Release in the Basal Ganglia of the Rat Brain by Dynorphin Peptides
J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1307 - 1315.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
J.-G. Li, L.-Y. Luo, J. G. Krupnick, J. L. Benovic, and L.-Y. Liu-Chen
U50,488H-induced Internalization of the Human {kappa} Opioid Receptor Involves a {beta}-Arrestin- and Dynamin-dependent Mechanism. {kappa} RECEPTOR INTERNALIZATION IS NOT REQUIRED FOR MITOGEN-ACTIVATED PROTEIN KINASE ACTIVATION
J. Biol. Chem., April 23, 1999; 274(17): 12087 - 12094.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Chen, J.-C. Xue, J. Zhu, Y.-W. Chen, S. Kunapuli, J. K. d. Riel, L. Yu, and L.-Y. Liu-Chen
Characterization of Irreversible Binding of [IMAGE]-Funaltrexamine to the Cloned Rat µ Opioid Receptor
J. Biol. Chem., July 28, 1995; 270(30): 17866 - 17870.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1992 by the American Society for Pharmacology and Experimental Therapeutics.